1. Home
  2. IFRX vs CMT Comparison

IFRX vs CMT Comparison

Compare IFRX & CMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IFRX
  • CMT
  • Stock Information
  • Founded
  • IFRX 2007
  • CMT 1996
  • Country
  • IFRX Germany
  • CMT United States
  • Employees
  • IFRX N/A
  • CMT N/A
  • Industry
  • IFRX Biotechnology: Pharmaceutical Preparations
  • CMT Electronic Components
  • Sector
  • IFRX Health Care
  • CMT Consumer Discretionary
  • Exchange
  • IFRX Nasdaq
  • CMT Nasdaq
  • Market Cap
  • IFRX 143.7M
  • CMT 156.7M
  • IPO Year
  • IFRX 2017
  • CMT N/A
  • Fundamental
  • Price
  • IFRX $2.24
  • CMT $16.17
  • Analyst Decision
  • IFRX Strong Buy
  • CMT Strong Buy
  • Analyst Count
  • IFRX 1
  • CMT 1
  • Target Price
  • IFRX $8.00
  • CMT $27.00
  • AVG Volume (30 Days)
  • IFRX 401.6K
  • CMT 43.0K
  • Earning Date
  • IFRX 11-08-2024
  • CMT 11-05-2024
  • Dividend Yield
  • IFRX N/A
  • CMT N/A
  • EPS Growth
  • IFRX N/A
  • CMT N/A
  • EPS
  • IFRX N/A
  • CMT 1.75
  • Revenue
  • IFRX $187,930.00
  • CMT $313,657,000.00
  • Revenue This Year
  • IFRX $435.15
  • CMT N/A
  • Revenue Next Year
  • IFRX $180.44
  • CMT $8.01
  • P/E Ratio
  • IFRX N/A
  • CMT $9.28
  • Revenue Growth
  • IFRX 177.12
  • CMT N/A
  • 52 Week Low
  • IFRX $1.17
  • CMT $14.64
  • 52 Week High
  • IFRX $2.82
  • CMT $21.00
  • Technical
  • Relative Strength Index (RSI)
  • IFRX 52.76
  • CMT 40.40
  • Support Level
  • IFRX $1.93
  • CMT $15.51
  • Resistance Level
  • IFRX $2.74
  • CMT $16.25
  • Average True Range (ATR)
  • IFRX 0.25
  • CMT 0.44
  • MACD
  • IFRX -0.06
  • CMT -0.10
  • Stochastic Oscillator
  • IFRX 34.88
  • CMT 4.63

About IFRX InflaRx N.V.

InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.

About CMT Core Molding Technologies Inc

Core Molding Technologies Inc operates in the engineered materials market as one operating segment as a molder of thermoplastic and thermoset structural products. It produces and sells molded products for varied markets, including medium and heavy-duty trucks, automobiles, power sports, construction and agriculture, building products, and other industrial markets. The processes include compression molding of sheet molding compound (SMC), resin transfer molding (RTM), liquid molding of dicyclopentadiene (DCPD), spray-up and hand-lay-up, direct long-fiber thermoplastics (D-LFT) and structural foam, and structural web injection molding (SIM). It operates operates in Columbus, Ohio; Gaffney, South Carolina; Winona, Minnesota; Matamoros and Escobedo, Mexico; and Cobourg, Ontario, Canada.

Share on Social Networks: